Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPEDE in advancing or metastatic prostate cancer
2004-000193-31Phase 2Unknown
- Sponsor
- University College London
- Start
- Aug 2020
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, abiraterone, enzalutamide, apalutamide, celecoxib and 7 more in prostate cancer (PCa) and prostate adenocarcinoma (10 arms), sponsored by University College London. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
docetaxelabirateroneenzalutamideapalutamidecelecoxib
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on 2004-000193-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000193-31.